Vaxcyte to Present at Guggenheim Emerging Outlook: Biotech Summit on Feb. 12

Vaxcyte announced that management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on February 12, 2026. The company's Phase 3 adult and Phase 2 infant clinical programs are evaluating VAX-31, a 31-valent pneumococcal conjugate vaccine candidate for invasive pneumococcal disease prevention. VAX-24, a 24-valent PCV candidate, is also being developed. The company's cell-free protein synthesis platform, XpressCF, is intended to accelerate the development of high-fidelity vaccines.